Results of Meeting
Released
Released
Announcement PDF
ASX/Media Release
18/09/2020
Results of General Meeting
Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a Real-World Evidence company that
develops remote patient monitoring technologies underpinned by a clinical services model, advises that a
General Meeting of shareholders was held today, 18 September 2020. The resolution put to the meeting
were passed on a poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the
Company advises that details of the poll result and the proxies received in respect of the resolution are set
out below:
Poll Results
For
Against
Abstain
105,910,156
-
-
Resolutions
1 – Approval of change of Company name
Summary of Proxy Votes Received
Resolutions
For
At Proxy
Holders
Discretion
Against
Abstain
1 – Approval of change of Company name
63,751,779
287,778
-
-
Release authorised by: Dr Michael Winlo, CEO and Managing Director
For further information:
Dr Michael Winlo
CEO
(08) 6559 2800
investors@emeraldclinics.com.au
Matt Wright
Media/investor relations
+61 (0) 451 896 420
matt@nwrcommunications.com.au
About Emerald Clinics Limited
Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company focussed on generating
Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient
monitoring software and technology. The Emerald model provides care while also co-creating high quality
and ethically sourced clinical data from informed and consenting patients. Emerald’s evidence is used to
accelerate the development of new treatments and models of care. Emerald customers pay for deidentified
data, clinical trials and consulting services or monitor their workforce.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, the
company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results
may differ materially from those indicated by such forward-looking statements as a results of various
important factors, including: the Company’s ability to successfully develop its product candidates and timely
complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its
product candidates. In addition, the forward-looking statements included in this press release represents the
Company’s views as of the date hereof. The Company anticipates that subsequent events and developments
will cause the Company’s views to change. However, while the Company may elect to update these forwardlooking statements at some point in the future, the Company specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as representing the Company’s views as of any
date subsequent to the date hereof.
Share your feedback
Discover